Pharmaceutical Company Announces Innovative Dry Eye Disease Treatment

Dry Eye Disease (DED) is a prevalent condition affecting millions globally, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. Despite the availability of various treatments, many patients continue to seek more effective solutions. In a significant development, OKYO Pharma has announced that its drug, OK-101, has achieved statistical significance in improving multiple signs and symptoms of DED, including ocular pain relief, in its Phase 2 trial. $OKYO Pharma(OKYO.US)$